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Homelessness and Adherence to Antiretroviral
Therapy among a Cohort of HIV-Infected Injection
Drug Users
ABSTRACT Homelessness is prevalent among HIV-infected injection drug users (IDU)
and may adversely affect access and adherence to antiretroviral therapy (ART).
There are limited descriptions of the effect of homelessness on adherence to ART in
long-term cohorts of HIV-infected IDU. We used data from a community-recruited
prospective cohort of HIV-infected IDU, including comprehensive ART dispensation
records, in a setting where HIV care is free. We examined the relationship between
the homelessness measured longitudinally, and the odds of ≥95% adherence to ART
using generalized estimating equations logistic regression modeling adjusting for
sociodemographics, drug use, and clinical variables. Between May 1996 and
September 2008, 545 HIV-infected IDU were recruited and eligible for the present
study. The median follow-up duration was 23.8 months (IQR 8.5–91.6 months)
contributing 2,197 person-years of follow-up. At baseline, homeless participants
were slightly younger (35.8 vs. 37.9 years, p=0.01) and more likely to inject heroin
at least daily (37.1% vs. 24.6%. p=0.004) than participants who had housing. The
multivariate model revealed that homelessness (adjusted odds ratio [AOR] 0.66; 95%
CI: 0.53–0.84) and frequent heroin use (AOR 0.40; 95% CI: 0.30–0.53) were
significantly and negatively associated with ART adherence, whereas methadone
maintenance was positively associated (AOR 2.33; 95% CI: 1.86–2.92). Sub-optimal
ART adherence was associated with homelessness and daily injection heroin use
among HIV-infected IDU. Given the survival benefit of ART, it is critical to develop
and evaluate innovative strategies such as supportive housing and methadone
maintenance to address these risk factors to improve adherence.
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INTRODUCTION
Despite dramatic advances in antiretroviral therapy (ART) resulting in improved
HIV treatment outcomes and survival,
1–4 HIV-infected injection drug users (IDU)
appear to have derived less beneﬁt than other HIV-infected populations.
5–7 There
are a myriad of reasons ranging from barriers to accessing ART
7,8 to decreased
adherence due to ongoing substance use
9–12 and inadequate integration of addiction
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13–15 Another contributing factor may be the physical and
social environments
16,17 where a signiﬁcant proportion of IDUs experience unstable
housing or homelessness.
18–20
Individuals who are unstably housed or homeless have a substantially increased
HIV/AIDS infection rate compared to persons who are housed.
21 Homeless persons
also have higher risks of serious morbidity and mortality, with the most frequently
reported causes of death being related to violence, HIV/AIDS, and substance
misuse.
22–26 Furthermore, homeless persons living with HIV have been found to be
less likely to access and receive optimal regular HIV care.
16,27–29 This may also
related to healthcare associated barriers, given that prescribing physicians may be
less likely to prescribe ART to these patients, although Bangsberg et al.
30
demonstrated that providers inaccurately estimated ART adherence compared to
structured patient report, which was more closely related to pill count among a
sample of homeless or unstably housed HIV-infected persons.
Although homeless IDU have been reported to have lower rates of adherence to
ART, active drug use and homelessness are states that can change over time and
long-term evaluations of the impact of homelessness on adherence are limited and
often conducted in settings with ﬁnancial barriers to care. Unlike previous studies
that have examined homelessness and HIV treatment adherence, the context of this
study is one where HIV care is universally available and ART is provided at no
charge.Thus,weusedthedataderivedfromalongstandingcommunity-basedcohortof
HIV-infected IDU with detailed data on housing status and drug use behaviors to
determine the longitudinal impact of homelessness on adherence to ART.
METHODS
Data for these analyses was derived from the AIDS Care Cohort to evaluate
Exposure to Survival Services (ACCESS), an ongoing prospective observational
cohort of HIV-infected illicit drug users in Vancouver, Canada. The methods for this
study have been previously described.
8,31,32 In brief, beginning in May 1996,
participants were recruited through snowball sampling and extensive street outreach
in the city’s Downtown Eastside neighborhood, the local epicenter of drug-related
HIV transmission. ACCESS eligibility criteria include: aged 18 years or older, HIV-
infected, having used illicit drugs other than cannibinoids in the previous month,
and having provided written informed consent. At baseline and every 6-month
follow-up interview, participants answer a standardized interviewer-administered
questionnaire, are examined by a study nurse and provide blood samples for
serologic analysis. The information on sociodemographic, drug uses and other
behavioral characteristics gathered at each interview is augmented with data on HIV
care and treatment outcomes from the British Columbia Centre for Excellence in
HIV/AIDS Drug Treatment Programme. This province-wide, centralized antiretro-
viral therapy dispensary and HIV/AIDS monitoring lab provides a complete
prospective proﬁle of CD4 cell counts, plasma HIV-1 RNA viral load, and
dispensation of speciﬁc antiretroviral agents for each participant.
8,31,32
Measures
In the present study, we included all participants who were HIV-infected who had a
baseline CD4 count and viral load measurement. The primary outcome of interest
was adherence to antiretroviral therapy. As in previous studies using this validated
and conﬁdential pharmacy dispensation data,
32–34 we measured adherence to
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over the number of days an individual was eligible for ART, and deﬁned adherence
as equal to or greater than 95% adherence to ART during this period.
33 The clinical
utility of this measure and its reliable prediction of virological suppression
10,32–36
and survival
32,33 has been previously shown. The primary explanatory variable,
homelessness, was deﬁned as living on the street or having no ﬁxed address in the
previous 6 months, which corresponded with the timeline of our primary outcome,
ART adherence variable.
We also considered other explanatory variables that might confound the
relationship between homelessness and ART adherence. These included demo-
graphic and socioeconomic characteristics such as age (per year older), gender
(female vs. male), Aboriginal ancestry (yes vs. no), educational attainment (Ghigh
school diploma vs. ≥ high school diploma), and legal employment (yes vs. no). Legal
employment referred to having salaried or temporary work at any time in the
previous 6 months. We also included the individual-level behavioral variables:
injection cocaine use (≥daily vs. Gdaily), injection heroin use (≥daily vs. Gdaily),
injection methamphetamine use (≥daily vs. Gdaily), and inhalation crack cocaine use
(≥daily vs. Gdaily). We also included current use of methadone maintenance
therapy. These variables were time-updated, referred to the 6-month period prior to
the interview, and were consistent with previous analyses.
32,37 Clinical variables
included were the baseline CD4+ cell count (per 100 cells/mm
3) and HIV-1 RNA
plasma viral load (per log10). For both measures, we used the mean of all available
observations in the previous 6 months; if none were available, we used the most
recent observation. Plasma HIV-1 RNA was measured using the Roche Amplicor
Monitor assay (Roche Molecular Systems, Mississauga, Canada). We also included
the year of the baseline interview to account for any cohort effects in ART
prescribing.
Statistical Analysis
We ﬁrst compared the baseline characteristics of the study sample stratiﬁed by
homelessness, using the chi-squared test for categorical variables and the Wilcoxon
rank-sum test for continuous variables. We then examined the bivariate relation-
ships between adherence and all explanatory variables over the study period using
generalized estimating equations logistic regression models employing an exchange-
able working correlation matrix.
38,39 This form of regression modeling was used to
account for the correlation between covariates gathered over time from the same
individual, and to estimate the independent effect of homelessness on the likelihood
of adherence to ART within each individual. There were 93 (17%) subjects who
never accessed ART during the follow-up period and they were categorized as being
non-adherent to ART. To account for possible confounding and calculate the best
effect estimate, we constructed a multivariate model using an a priori deﬁned
modeling strategy suggested by Greenland et al.
40 First, we ﬁt a full model including
the primary explanatory and all secondary explanatory variables. Using a manual
stepwise approach, we constructed reduced models, each with one variable removed
from the full set of secondary explanatory variables. Comparing the value of the
coefﬁcient for the primary explanatory in the full model and each of the reduced
models, we removed the secondary explanatory corresponding to the smallest
relative change. We continued this process until the maximum change from the full
model exceeded 5%. Several authors have successfully used this technique to
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explanatory variable.
40–42 We also examined selected interaction terms.
RESULTS
Between May 1996 and April 2008, there were 545 HIV-infected individuals who
were eligible for the present study. The median follow-up duration was 23.8 months
(IQR 8.5–91.6 months) contributing to 2,197 person-years of follow-up. The
characteristics of participants who were homeless at baseline are presented in
Table 1. There were 143 (26.2%) IDU who were homeless at baseline. There were
no signiﬁcant differences at baseline between the participants who were homeless
and those who were not, other than that they were slightly younger (35.8 years vs.
37.9 years, p=0.01) and that they were more likely to inject heroin at least daily
(37.1% vs. 24.6%. p=0.004).
During the study period, there were 1,186 (26.6%) observations that were 95%
adherent, out of 4,460 total observations. Table 2 presents the bivariate association
between each explanatory variable on ART adherence over the study period.
Participants who were homeless were less likely to be adherent to ART (odds ratio
[OR] 0.62; 95% CI: 0.50–0.77). Female sex, lower educational attainment, frequent
alcohol use, and injection drug use were negatively associated with ART adherence,
whereas older age, methadone maintenance therapy, and time since the baseline
interview were positively associated with adherence to ART.
The multivariate model result is depicted in Figure 1 and illustrates that after
adjustment, homelessness (adjusted odds ratio [AOR] 0.66; 95% CI: 0.53–0.84) and
frequent heroin use (AOR 0.40; 95% CI: 0.30–0.53) were signiﬁcantly and
negatively associated with ART adherence adjusting for baseline CD4 count and
baseline plasma viral load. Methadone maintenance therapy was positively
associated with ART adherence (AOR 2.33; 95% CI: 1.86–2.92). There were no
signiﬁcant interactions.
DISCUSSION
In this long-term prospective study of HIV-infected IDU, we found that homelessness
and at least daily heroin use were negatively associated with ART adherence,
whereas methadone maintenance was positively associated with adherence to ART.
It has been previously shown that HIV-infected IDU who are able to achieve the
95% level of adherence derive the clinical beneﬁts of treatment through HIV-1 RNA
viral suppression and CD4 cell count rise.
10,43
A number of studies have also found that ART adherence is negatively
associated with ongoing drug use.
9,11,12,36 These studies have emphasized the
importance of addressing addiction issues for HIV-infected IDU to optimize HIV
treatment outcomes. Lucas et al.
44 recently reported a small randomized controlled
trial comparing clinic-based buprenorphine-naloxone (BUP) versus off-site referral
for opiate treatment for HIV-infected opioid-dependent patients and found that
integrating BUP in the clinic setting increased access to addiction treatment and
improved substance abuse treatment outcomes. Methadone maintenance therapy
has also been shown to improve ART adherence and HIV treatment outcomes in
variety of settings.
34,37,45,46
Homelessness in and of itself represents a signiﬁcant structural risk factor for
increased morbidity and mortality,
22,23,25,47 and for HIV-infected drug and alcohol
PALEPU ET AL. 548users who are homeless, their existing vulnerabilities are further heightened.
48
Homelessness among HIV-infected IDU may affect ART adherence through a
multitude of mechanisms, including poor access to regular meals and water, lack of
a ﬁxed daily routine, no place to store the medication, lack of privacy, and stigma, as
TABLE 1 Selected sociodemographic, behavioral, and clinical characteristics at baseline,
stratiﬁed by homelessness in ACCESS (n=545 participants)
Characteristic
Homelessness
OR
a 95% CI
b p Value
Yes No
143 (26.2) 402 (73.8)
Age
Median (IQR) 35.8 (29.1–42.3) 37.9 (31.8–43.9) 0.97 0.95–0.99 0.01
Gender
Male 95 (66.4) 246 (61.2) 1.00
Female 48 (33.6) 156 (38.8) 0.80 0.53–1.19 0.266
Aboriginal ancestry
No 96 (67.1) 264 (65.7) 1.00
Yes 47 (32.9) 138 (34.4) 0.94 0.62–1.40 0.751
Educational attainment
≥ High school diploma 124 (86.7) 345 (85.8) 1.00
GHigh school diploma 19 (13.3) 57 (14.2) 0.93 0.53–1.62 0.791
Formal employment
No 115 (80.4) 350 (87.1) 1.00
Yes 28 (19.6) 52 (12.9) 1.64 0.99–2.72 0.054
Frequent alcohol use
GDaily 129 (90.2) 348 (86.6) 1.00
≥Daily 14 (9.8) 54 (13.4) 0.70 0.38–1.30 0.258
Frequent crack cocaine use
GDaily 100 (69.9) 313 (77.9) 1.00
≥Daily 43 (30.1) 89 (22.1) 1.51 0.99–2.32 0.06
Frequent cocaine injection
GDaily 92 (64.3) 261 (4.9) 1.00
≥Daily 51 (35.7) 141 (35.1) 1.03 0.69–1.53 0.899
Frequent heroin injection
GDaily 90 (62.9) 303 (75.4) 1.00
≥Daily 53 (37.1) 99 (24.6) 1.80 1.20–2.71 0.004
Frequent speedball injection
GDaily 123 (86.0) 344 (85.6) 1.00
≥Daily 20 (14) 58 (14.4) 0.96 0.56–1.67 0.897
Frequent crystal meth injection
GDaily 140 (97.9) 395 (98.3) 1.00
≥Daily 3 (2.1) 7 (1.7) 1.21 0.31–4.74 0.727
Current methadone maintenance therapy
No 100 (69.9) 276 (68.7) 1.00
Yes 43 (30.1) 126 (31.3) 0.94 0.62–1.42 0.777
CD4+ cell count
Median (IQR) 100 cells/mm3 3.5 (2.1–5.3) 3.4 (2.1–4.7) 1.04 0.96–1.12 0.532
HIV-1 RNA viral load
Median (IQR) per log10 4.3 (2.9–4.9) 4.2 (2.6–4.8) 1.06 0.92–1.23 0.472
aOdds ratio
b95% Conﬁdence interval
HOMELESSNESS AND ANTIRETROVIRAL THERAPY ADHERENCE TO ANTIRETROVIRAL THERAPY 549TABLE 2 Bivariate GEE logistic regression analysis of explanatory variables and ART adherence
in ACCESS (n=545 participants contributed to 4,460 observations)
Characteristic OR
a 95% CI
b p Value
Homelessness
c
No 1.00
Yes 0.62 0.50–0.77 G0.001
Age
(per year) 1.06 1.04–1.08 G0.001
Gender
Male 1.00
Female 0.69 0.52–0.89 0.006
Aboriginal ancestry
No 1.00
Yes 0.97 0.74–1.28 0.84
Formal employment
c
No 1.00
Yes 1.11 0.87–1.41 0.40
Educational attainment
≥High school diploma 1.00
GHigh school diploma 0.56 0.37–0.85 0.007
Frequent alcohol use
c
GDaily 1.00
≥Daily 0.64 0.47–0.86 0.004
Frequent crack cocaine use
c
GDaily 1.00
≥Daily 0.94 0.78–1.13 0.51
Frequent cocaine use, injection
c
GDaily 1.00
≥Daily 0.48 0.40–0.57 G0.001
Frequent heroin use, injection
c
GDaily 1.00
≥Daily 0.38 0.30–0.48 G0.001
Frequent speedball use, injection
c
GDaily 1.00
≥Daily 0.34 0.25–0.48 G0.001
Frequent methamphetamine use, injection
c
GDaily 1.00
≥Daily 0.70 0.44–1.14 0.15
Methadone maintenance therapy
No 1.00
Yes 2.44 2.01–2.96 G0.001
CD4 cell count
Per 100 cells/mm
3 0.94 0.89–0.99 0.047
Per log10 unit increase 0.54 0.48–0.60 G0.001
GEE generalized estimating equations
aOdds ratio
b95% Conﬁdence interval
cRefers to the 6-month period prior to the interview
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15 Given the complexity of managing their
health, it is not surprising that case management has been shown to be positively
associated with ART adherence and improved HIV treatment outcomes among
homeless HIV-infected persons.
49
Directly administered ART or modiﬁed directly observed ART administration
among HIV-infected IDU or persons with substance dependence have been evaluated
in randomized trials and have found improved adherence and HIV treatment
outcomes.
50–53 One study followed patients after the directly administered ART
intervention when they went to self-administration and found no difference in viral
suppression at 6 months after the end of the trial, suggesting that ongoing strategies
are required to maintain the initial beneﬁt.
54
A focus on individual-level behaviors alone may not be effective in improving
ART adherence, especially in the context of homelessness or unstable housing.
Strategies that address broader determinants of health, such as housing, for this
vulnerable group are more likely to be effective in creating the social and physical
environments that reduce the ongoing risks for non-adherence and other HIV-risk
behavior.
16,55 The Housing and Health randomized trial of the effects of Housing
Opportunities for People with AIDS rental assistance on the health and risk behavior
of homeless and unstably housed HIV-infected persons was recently reported.
56
They noted a signiﬁcant increase in stable housing status over time for both the
intervention and control group; however, it was higher for the intervention group at
18 months (82.5% vs. 50.6%, pG0.0001). In terms of health outcomes, there was
no difference between groups in the proportion non-adherent to ART or new uptake
of ART. The intervention group reported more appropriate medical care, had better
mental and physical health scores, and lower stress than the control group.
56 The
power to detect differences between groups was attenuated by the higher-than-
expected movement into housing among the control group in this trial. In contrast,
the Chicago Housing for Health Partnership randomized trial examined the
effect of a housing and case management program for hospitalized homeless
persons with HIV who were ready for discharge, and found that more of the
intervention group were alive after 12 months and had CD4 counts ≥200 cells/
mm
3 (55% vs. 34%, p=0.04). Unfortunately, they do not report on ART
medication adherence.
57 The housing model used in this study was “Housing
First”
58,59 and there were no sobriety or treatment adherence requirements for the
participants, unlike housing ready models.
FIGURE 1. Multivariable logistic regression model using GEE of factors associated with 95%
antiretroviral therapy adherence.
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infected participants and this is not feasible as no registry of all HIV-infected
individuals, particularly illicit drug users, exists. This may limit the generalizability of
our results to other settings. Our pharmacy reﬁll measure may be an overestimation of
adherence in our sample as we do not know if the study participants ingested their
medication, although the measure has proven to be a potent predictor of virologic
suppression and mortality among HIV-infected persons.
32–34
In summary, we found that over a quarter of our HIV-infected IDU were
homeless at baseline and that in our longitudinal analysis, homelessness and
frequent heroin use were negatively associated with ART adherence. Only
methadone maintenance was positively associated with adherence. Given the high
morbidity and mortality associated with sub-optimal ART adherence, future studies
should evaluate innovative interventions that strengthen the links between
supportive housing and addiction treatment for HIV-infected IDU.
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